Relationship between antithrombotic drugs and postoperative outcomes in patients with gastric cancer after gastrectomy : a propensity matching analysis
© 2023. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association..
BACKGROUND: As there is no consensus on the impact of antithrombotic drugs on post-gastrectomy outcomes in gastric cancer patients, this study aimed to investigate the impact of antithrombotic drugs on postoperative outcomes in these patients after gastrectomy.
METHODS: Patients with Stage I-III primary gastric cancer who underwent radical gastrectomy between April 2005 and May 2022 were included. We performed propensity score matching to adjust for patient background and compared bleeding complications. Multivariate analysis with logistic regression analysis was performed to identify risk factors associated with bleeding complications.
RESULTS: Of the 6798 patients, 310 (4.6%) were in the antithrombotic group and 6488 (95.4%) were in the non-antithrombotic group. Twenty-six patients (0.38%) experienced bleeding complications. After matching, the number of patients in each group was 300, with insignificant differences in any factor. A comparison of postoperative outcomes showed no difference in bleeding complications (P = 0.249). In the antithrombotic group, 39 (12.6%) continued drugs, and 271 (87.4%) discontinued them before surgery. After matching, there were 30 and 60 patients, respectively, with no differences in patient background. A comparison of postoperative outcomes showed no differences in bleeding complications (P = 0.551). In multivariate analysis, antithrombotic drug use and continuation of antiplatelet agents were not risk factors for bleeding complications.
CONCLUSION: Antithrombotic drugs and its continuation may not worsen bleeding complications in patients with gastric cancer after radical gastrectomy. Bleeding complications were rare, and further studies are needed on risk factors for bleeding complications in larger databases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 26(2023), 5 vom: 16. Sept., Seite 833-842 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matsui, Ryota [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulant drug |
|---|
| Anmerkungen: |
Date Completed 24.07.2023 Date Revised 30.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10120-023-01410-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358302374 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358302374 | ||
| 003 | DE-627 | ||
| 005 | 20231226074442.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-023-01410-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358302374 | ||
| 035 | |a (NLM)37328674 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matsui, Ryota |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relationship between antithrombotic drugs and postoperative outcomes in patients with gastric cancer after gastrectomy |b a propensity matching analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.07.2023 | ||
| 500 | |a Date Revised 30.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s) under exclusive licence to The International Gastric Cancer Association and The Japanese Gastric Cancer Association. | ||
| 520 | |a BACKGROUND: As there is no consensus on the impact of antithrombotic drugs on post-gastrectomy outcomes in gastric cancer patients, this study aimed to investigate the impact of antithrombotic drugs on postoperative outcomes in these patients after gastrectomy | ||
| 520 | |a METHODS: Patients with Stage I-III primary gastric cancer who underwent radical gastrectomy between April 2005 and May 2022 were included. We performed propensity score matching to adjust for patient background and compared bleeding complications. Multivariate analysis with logistic regression analysis was performed to identify risk factors associated with bleeding complications | ||
| 520 | |a RESULTS: Of the 6798 patients, 310 (4.6%) were in the antithrombotic group and 6488 (95.4%) were in the non-antithrombotic group. Twenty-six patients (0.38%) experienced bleeding complications. After matching, the number of patients in each group was 300, with insignificant differences in any factor. A comparison of postoperative outcomes showed no difference in bleeding complications (P = 0.249). In the antithrombotic group, 39 (12.6%) continued drugs, and 271 (87.4%) discontinued them before surgery. After matching, there were 30 and 60 patients, respectively, with no differences in patient background. A comparison of postoperative outcomes showed no differences in bleeding complications (P = 0.551). In multivariate analysis, antithrombotic drug use and continuation of antiplatelet agents were not risk factors for bleeding complications | ||
| 520 | |a CONCLUSION: Antithrombotic drugs and its continuation may not worsen bleeding complications in patients with gastric cancer after radical gastrectomy. Bleeding complications were rare, and further studies are needed on risk factors for bleeding complications in larger databases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticoagulant drug | |
| 650 | 4 | |a Antiplatelet drug | |
| 650 | 4 | |a Antithrombotic therapy | |
| 650 | 4 | |a Gastric cancer | |
| 650 | 4 | |a Postoperative complication | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 700 | 1 | |a Nunobe, Souya |e verfasserin |4 aut | |
| 700 | 1 | |a Makuuchi, Rie |e verfasserin |4 aut | |
| 700 | 1 | |a Hayami, Masaru |e verfasserin |4 aut | |
| 700 | 1 | |a Ida, Satoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kumagai, Koshi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohashi, Manabu |e verfasserin |4 aut | |
| 700 | 1 | |a Sano, Takeshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association |d 1998 |g 26(2023), 5 vom: 16. Sept., Seite 833-842 |w (DE-627)NLM115990356 |x 1436-3305 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:5 |g day:16 |g month:09 |g pages:833-842 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10120-023-01410-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 5 |b 16 |c 09 |h 833-842 | ||